Nasdaq adds Moderna Inc. stock to the Nasdaq-100 index

Published on 10/07/2026 at 14:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 145.00 million, up 2.10 percent year over year. Moderna Inc. stock costs EUR 164.69 on October 7, 2026 after EUR 166.88.

Isometrische 3D-Grafik zeigt Pharma-Wertschöpfungskette von Labor bis Krankenhaus — Moderna Inc. (US60770K1034) illustriert die isometrische Wertschöpfungskette der Biotech-Branche von Forschung bis zur finalen Auslieferung, Illustration mit AI erstellt.

Moderna Inc. (ISIN US60770K1079) was trading at EUR 164.69 at Lang & Schwarz on October 7, 2026 at 2:31 p.m. CEST, down 1.31 percent from the prior close of EUR 166.88. The key company event is Nasdaq's decision to add Moderna to the Nasdaq-100 index before market open on October 9, 2026, as reported by FinanzNachrichten on October 1, 2026.

Index inclusion changes the setup

The Nasdaq-100 move replaces Warner Bros. Discovery and gives Moderna a new position in a benchmark tracked by more than 200 investment products with over USD 800 billion in assets, according to the same Nasdaq announcement carried by FinanzNachrichten.

That mechanical change matters because index-tracking funds must adjust holdings around the effective date. It does not change Moderna's operating results, so the stock's valuation still depends on the company's pipeline and commercial execution.

Revenue beat but losses persist

Moderna reported USD 145.00 million of revenue in the second quarter of 2026, compared with analyst estimates of USD 102.93 million, while revenue increased 2.10 percent from the second quarter of 2025. MarketBeat reported the figures on October 6, 2026.

The adjusted loss was USD 1.97 per share, narrower than the USD 2.03 consensus loss and better than the USD 2.13 loss reported for the second quarter of 2025. The comparison shows improving quarterly revenue and earnings performance, but the loss still keeps profitability as a central test for the investment case.

Analyst targets trail the rally

MarketBeat counted seven Buy ratings, 13 Hold ratings and five Sell ratings on October 6, 2026, producing a Hold consensus and an average price target of USD 77.83. The same report cited a USD 196.648 market price, making the target gap a clear counterweight to the index event.

Moderna's operating expansion also remains visible in management changes. A September 30, 2026 release carried by FinanzNachrichten said Juan Andres would become chief operating officer effective October 5, 2026, as Moderna expands its oncology operations.

Stock stays tied to execution

Moderna's market capitalization was USD 74.4 billion as of October 6, 2026, while its primary-exchange 52-week range was USD 22.28 to USD 212.22. The figures put the company's recent rise beside a still-wide trading history and underline why the upcoming index change is only one part of the market debate.

At Lang & Schwarz, Moderna stock was trading at EUR 164.69 on October 7, 2026 at 2:31 p.m. CEST, down 1.31 percent versus the Lang & Schwarz prior close of EUR 166.88 on October 6, 2026. The further course of trading is shown by the continuously updated real-time quote of Moderna Inc. stock.